Keyword: Yervoy

Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.

Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.

After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.

Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.

Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.

The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.

The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.

Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.

California startup Pionyr is using $62 million of VC-backed funding to target antibodies in the tumor microenvironment.

Scientists from the University of Chicago and Mount Sinai are exploring different methods of improving checkpoint-inhibiting cancer drugs.